RU2015143859A - Замедленное высвобождение биматопроста, аналогов биматопроста, простамидов и простагландинов для уменьшения отложений жира - Google Patents
Замедленное высвобождение биматопроста, аналогов биматопроста, простамидов и простагландинов для уменьшения отложений жира Download PDFInfo
- Publication number
- RU2015143859A RU2015143859A RU2015143859A RU2015143859A RU2015143859A RU 2015143859 A RU2015143859 A RU 2015143859A RU 2015143859 A RU2015143859 A RU 2015143859A RU 2015143859 A RU2015143859 A RU 2015143859A RU 2015143859 A RU2015143859 A RU 2015143859A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- fat
- bimatoprost
- deposits
- release
- Prior art date
Links
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 title claims 15
- 229960002470 bimatoprost Drugs 0.000 title claims 12
- 150000003180 prostaglandins Chemical class 0.000 title claims 6
- 229940094443 oxytocics prostaglandins Drugs 0.000 title claims 3
- 239000000203 mixture Substances 0.000 claims 28
- 238000000034 method Methods 0.000 claims 11
- 238000013268 sustained release Methods 0.000 claims 7
- 239000012730 sustained-release form Substances 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 230000008021 deposition Effects 0.000 claims 6
- 239000007943 implant Substances 0.000 claims 5
- 238000002347 injection Methods 0.000 claims 5
- 239000007924 injection Substances 0.000 claims 5
- 210000000577 adipose tissue Anatomy 0.000 claims 4
- 229960001160 latanoprost Drugs 0.000 claims 3
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 2
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 claims 2
- 210000000579 abdominal fat Anatomy 0.000 claims 2
- 230000037444 atrophy Effects 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 229920002674 hyaluronan Polymers 0.000 claims 2
- 229960003160 hyaluronic acid Drugs 0.000 claims 2
- 239000004005 microsphere Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 210000004003 subcutaneous fat Anatomy 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 229960002368 travoprost Drugs 0.000 claims 2
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 claims 2
- LLKFNPUXQZHIAE-UHFFFAOYSA-N 5-(3-aminopropyl)-8-bromo-3-methyl-2h-pyrazolo[4,3-c]quinolin-4-one Chemical compound O=C1N(CCCN)C2=CC=C(Br)C=C2C2=C1C(C)=NN2 LLKFNPUXQZHIAE-UHFFFAOYSA-N 0.000 claims 1
- 244000025254 Cannabis sativa Species 0.000 claims 1
- 210000001789 adipocyte Anatomy 0.000 claims 1
- 229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 claims 1
- 210000001593 brown adipocyte Anatomy 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 210000000636 white adipocyte Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361811682P | 2013-04-12 | 2013-04-12 | |
| US61/811,682 | 2013-04-12 | ||
| PCT/US2014/033558 WO2014169075A1 (en) | 2013-04-12 | 2014-04-09 | Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015143859A true RU2015143859A (ru) | 2017-05-16 |
| RU2015143859A3 RU2015143859A3 (enExample) | 2018-03-05 |
Family
ID=51686960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015143859A RU2015143859A (ru) | 2013-04-12 | 2014-04-09 | Замедленное высвобождение биматопроста, аналогов биматопроста, простамидов и простагландинов для уменьшения отложений жира |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20140308354A1 (enExample) |
| EP (2) | EP2983663B1 (enExample) |
| JP (1) | JP2016520561A (enExample) |
| KR (1) | KR20150141972A (enExample) |
| CN (2) | CN105101962A (enExample) |
| AU (2) | AU2014250937A1 (enExample) |
| BR (1) | BR112015025915A8 (enExample) |
| CA (1) | CA2908731A1 (enExample) |
| CL (1) | CL2015003023A1 (enExample) |
| DK (1) | DK2983663T3 (enExample) |
| ES (1) | ES2785382T3 (enExample) |
| IL (1) | IL242006B (enExample) |
| MX (1) | MX381097B (enExample) |
| MY (1) | MY187802A (enExample) |
| RU (1) | RU2015143859A (enExample) |
| SG (2) | SG10202109919PA (enExample) |
| WO (1) | WO2014169075A1 (enExample) |
| ZA (1) | ZA201507217B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2983942A1 (en) * | 2015-04-30 | 2016-11-03 | Allergan, Inc. | Cosmetic method and therapeutic use for fat reduction |
| US11452703B2 (en) * | 2020-05-21 | 2022-09-27 | Peregrine Ophthalmic PTE LTD. | Methods and compositions for reducing adipocyte numbers |
| BR112023001073A2 (pt) * | 2020-07-21 | 2023-03-07 | Allergan Inc | Implante intraocular com alto carregamento de prostamida |
| WO2024218609A1 (en) * | 2023-04-18 | 2024-10-24 | Welfare Concepts Limited | Composition and method for inducing luteolysis |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2218424A (en) * | 1931-05-07 | 1940-10-15 | Teleregister Corp | Transmitter and code translator |
| US4525359A (en) * | 1982-12-10 | 1985-06-25 | Greenway Frank L Iii | Treatment for selective weight control |
| US6124344A (en) | 1993-12-28 | 2000-09-26 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| ES2159734T3 (es) * | 1995-05-18 | 2001-10-16 | Allergan Sales Inc | Derivados 2-heteroarilalquenilicos del acido ciclopentano-heptan(en)oico como agentes terapeuticos para el tratamiento de la hipertension ocular. |
| US8114911B2 (en) | 2002-10-23 | 2012-02-14 | Sucampo Ag | Prostaglandin compounds for the treatment of obesity |
| EP1568359A4 (en) * | 2002-12-04 | 2011-05-18 | Santen Pharmaceutical Co Ltd | DRUG DELIVERY SYSTEM HAVING SUB-CONJUNCTIVAL DEPOSIT |
| AU2004308971A1 (en) * | 2003-12-22 | 2005-07-14 | Aventis Pharmaceuticals Inc. | Injectable phosphatidylcholine preparations |
| US20080038316A1 (en) | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
| US7666912B2 (en) * | 2006-03-23 | 2010-02-23 | Massachusetts Eye And Ear Infirmary | Compositions and methods for reducing body fat |
| MX2009004198A (es) * | 2006-10-17 | 2009-10-19 | Lithera Inc | Metodos, composiciones y formulaciones para el tratamiento de enfermedad ocular tiroidea. |
| US8969415B2 (en) * | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US9095506B2 (en) * | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| US20100247606A1 (en) * | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
| US20130071349A1 (en) * | 2010-03-02 | 2013-03-21 | Allergan, Inc. | Biodegradable polymers for lowering intraocular pressure |
| US20120022137A1 (en) | 2010-07-21 | 2012-01-26 | Rivers Hongwen M | METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS |
| BR122019025507B1 (pt) * | 2013-03-15 | 2021-01-12 | Allergan, Inc. | implante intraocular biodegradável contendo prostamida e seu uso |
| CA2983942A1 (en) | 2015-04-30 | 2016-11-03 | Allergan, Inc. | Cosmetic method and therapeutic use for fat reduction |
-
2014
- 2014-04-09 CA CA2908731A patent/CA2908731A1/en not_active Abandoned
- 2014-04-09 KR KR1020157029970A patent/KR20150141972A/ko not_active Ceased
- 2014-04-09 AU AU2014250937A patent/AU2014250937A1/en not_active Abandoned
- 2014-04-09 RU RU2015143859A patent/RU2015143859A/ru not_active Application Discontinuation
- 2014-04-09 EP EP14725582.2A patent/EP2983663B1/en active Active
- 2014-04-09 CN CN201480020790.8A patent/CN105101962A/zh active Pending
- 2014-04-09 DK DK14725582.2T patent/DK2983663T3/da active
- 2014-04-09 CN CN201910977574.7A patent/CN110840899A/zh active Pending
- 2014-04-09 MY MYPI2015002531A patent/MY187802A/en unknown
- 2014-04-09 SG SG10202109919P patent/SG10202109919PA/en unknown
- 2014-04-09 US US14/248,898 patent/US20140308354A1/en not_active Abandoned
- 2014-04-09 ES ES14725582T patent/ES2785382T3/es active Active
- 2014-04-09 MX MX2015014320A patent/MX381097B/es unknown
- 2014-04-09 EP EP20152147.3A patent/EP3656375A1/en not_active Withdrawn
- 2014-04-09 BR BR112015025915A patent/BR112015025915A8/pt active Search and Examination
- 2014-04-09 SG SG10201701938PA patent/SG10201701938PA/en unknown
- 2014-04-09 WO PCT/US2014/033558 patent/WO2014169075A1/en not_active Ceased
- 2014-04-09 JP JP2016507645A patent/JP2016520561A/ja active Pending
-
2015
- 2015-09-29 ZA ZA2015/07217A patent/ZA201507217B/en unknown
- 2015-10-09 CL CL2015003023A patent/CL2015003023A1/es unknown
- 2015-10-11 IL IL242006A patent/IL242006B/en active IP Right Grant
-
2016
- 2016-04-21 US US15/134,792 patent/US10682361B2/en active Active
-
2019
- 2019-05-08 AU AU2019203214A patent/AU2019203214B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| MX2015014320A (es) | 2015-12-08 |
| CN105101962A (zh) | 2015-11-25 |
| EP3656375A1 (en) | 2020-05-27 |
| US10682361B2 (en) | 2020-06-16 |
| AU2019203214A1 (en) | 2019-05-30 |
| AU2019203214B2 (en) | 2020-10-29 |
| SG10201701938PA (en) | 2017-04-27 |
| CA2908731A1 (en) | 2014-10-16 |
| AU2014250937A1 (en) | 2015-10-22 |
| KR20150141972A (ko) | 2015-12-21 |
| JP2016520561A (ja) | 2016-07-14 |
| MX381097B (es) | 2025-03-12 |
| RU2015143859A3 (enExample) | 2018-03-05 |
| WO2014169075A1 (en) | 2014-10-16 |
| DK2983663T3 (da) | 2020-04-20 |
| NZ712804A (en) | 2021-02-26 |
| CL2015003023A1 (es) | 2016-06-10 |
| US20160339039A1 (en) | 2016-11-24 |
| ES2785382T3 (es) | 2020-10-06 |
| BR112015025915A8 (pt) | 2020-01-14 |
| HK1221406A1 (en) | 2017-06-02 |
| CN110840899A (zh) | 2020-02-28 |
| EP2983663A1 (en) | 2016-02-17 |
| MY187802A (en) | 2021-10-26 |
| ZA201507217B (en) | 2017-09-27 |
| BR112015025915A2 (pt) | 2017-07-25 |
| EP2983663B1 (en) | 2020-01-22 |
| IL242006B (en) | 2020-04-30 |
| SG10202109919PA (en) | 2021-10-28 |
| US20140308354A1 (en) | 2014-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015143859A (ru) | Замедленное высвобождение биматопроста, аналогов биматопроста, простамидов и простагландинов для уменьшения отложений жира | |
| EA200970348A1 (ru) | Новые инъецируемые депо-композиции и способ получения таких композиций | |
| RU2011143860A (ru) | Безфосфатный лекарственный препарат для лечения глаукомы | |
| RU2011140433A (ru) | Внутриглазные системы доставки лекарственного средства с замедленным высвобождением и способы лечения глазных заболеваний | |
| CA2907721A1 (en) | Compositions and methods for topical delivery of prostaglandins to subcutaneous fat | |
| EA201401348A1 (ru) | Технология приготовления имплантируемой формы палиперидона | |
| PE20191492A1 (es) | Composicion farmaceutica que comprende selexipag | |
| WO2013037479A8 (en) | Ophthalmic compositions comprising prostaglandin f2 alpha derivatives and hyaluronic acid | |
| PE20120204A1 (es) | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas | |
| AU2003222049A1 (en) | Prostaglandin F2 alpha analogs in combination with antimicrobials for treating glaucoma | |
| UA104945C2 (uk) | Фармацевтична композиція лігандів рецепторів секретагогів гормону росту | |
| SI3085381T1 (en) | Orodispersible desmopressin to increase the initial sleep period without disturbing the nostrils | |
| AU2017261303A1 (en) | Ophthalmic compositions | |
| HRP20140676T1 (hr) | Formulacije deoksikolne kiseline i njezinih soli | |
| KR20030016418A (ko) | 고안압증 및 녹내장의 치료를 위한 조성물 | |
| ES2764654T3 (es) | Combinaciones de prostaglandinas y donantes de óxido nítrico | |
| JP2016520561A5 (enExample) | ||
| PH12012501349A1 (en) | Dp2 antagonist and uses thereof | |
| US20120263803A1 (en) | Aqueous ophthalmic composition | |
| US9101627B2 (en) | Pharmaceutical compositions containing bradykinin antagonists and hyaluronic acid, and uses thereof | |
| TW201347774A (zh) | 脂肪酸衍生物－聚合物共軛物 | |
| ES2431640T3 (es) | Composición oftálmica que comprende éster isopropílico de unoprostona y un agente de viscosidad | |
| WO2014183018A3 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES THROUGH INHIBITING TGF-β ACTIVITY | |
| CN117015391A (zh) | 用于由于衰老引起的骨骼肌功能衰退的肌肉功能改善剂 | |
| JP2019137698A (ja) | Ｌｈｒｈアナログの水性持続放出組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20210301 |